BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24198203)

  • 1. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.
    Shen Y; Tang D; Yao R; Wang M; Wang Y; Yao Y; Li X; Zhang H
    Med Oncol; 2013 Dec; 30(4):750. PubMed ID: 24198203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer.
    Gu YF; Zhang H; Su D; Mo ML; Song P; Zhang F; Zhang SC
    Chin Med J (Engl); 2013 Dec; 126(23):4435-9. PubMed ID: 24286402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
    Giovannetti E; Zucali PA; Peters GJ; Cortesi F; D'Incecco A; Smit EF; Falcone A; Burgers JA; Santoro A; Danesi R; Giaccone G; Tibaldi C
    Mol Cancer Ther; 2010 Mar; 9(3):581-93. PubMed ID: 20159991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
    Giaccone G; Iacona RB; Fandi A; Janas M; Ochs JS; Herbst RS; Johnson DH
    J Cancer Res Clin Oncol; 2009 Mar; 135(3):467-76. PubMed ID: 18787840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.
    Voortman J; Goto A; Mendiboure J; Sohn JJ; Schetter AJ; Saito M; Dunant A; Pham TC; Petrini I; Lee A; Khan MA; Hainaut P; Pignon JP; Brambilla E; Popper HH; Filipits M; Harris CC; Giaccone G
    Cancer Res; 2010 Nov; 70(21):8288-98. PubMed ID: 20978195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.
    Taniguchi K; Okami J; Kodama K; Higashiyama M; Kato K
    Cancer Sci; 2008 May; 99(5):929-35. PubMed ID: 18325048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib.
    Azuma K; Komatsu N; Hattori S; Matsueda S; Kawahara A; Sasada T; Itoh K; Hoshino T
    PLoS One; 2014; 9(1):e86667. PubMed ID: 24497964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
    J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
    Kimura H; Kasahara K; Shibata K; Sone T; Yoshimoto A; Kita T; Ichikawa Y; Waseda Y; Watanabe K; Shiarasaki H; Ishiura Y; Mizuguchi M; Nakatsumi Y; Kashii T; Kobayashi M; Kunitoh H; Tamura T; Nishio K; Fujimura M; Nakao S
    J Thorac Oncol; 2006 Mar; 1(3):260-7. PubMed ID: 17409866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
    Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
    PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
    Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
    Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.
    Yoshida K; Yatabe Y; Park J; Ogawa S; Park JY; Shimizu J; Horio Y; Matsuo K; Mitsudomi T; Hida T
    J Cancer Res Clin Oncol; 2010 Apr; 136(4):527-35. PubMed ID: 19777258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
    Han Y; Xu JM; Duan HQ; Zhang Y; Liu XQ; Zhang JS
    Chin J Cancer; 2010 Jan; 29(1):69-75. PubMed ID: 20038315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mathematical model for microRNA in lung cancer.
    Kang HW; Crawford M; Fabbri M; Nuovo G; Garofalo M; Nana-Sinkam SP; Friedman A
    PLoS One; 2013; 8(1):e53663. PubMed ID: 23365639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
    Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K
    Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
    Takeda M; Okamoto I; Nakagawa K
    J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
    Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
    J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.